



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|-----------------------|---------------------|------------------|
| 09/888,079 | 06/22/2001 | Signe Erickson Varner | 55821 (71699) | 6574 |
| 21874 | 7590 | 02/24/2005 | EXAMINER | |
| EDWARDS & ANGELL, LLP P.O. BOX 55874 BOSTON, MA 02205 | | | DESAUTO, MATTHEW F | |
| | | ART UNIT | PAPER NUMBER | |
| | | 3763 | | |

DATE MAILED: 02/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

41

| | | |
|---|--------------------------------------|--------------------------------------|
| Advisory Action Before the Filing of an Appeal Brief | Application No. 09/888,079 | Applicant(s) VARNER ET AL. |
| | Examiner Matthew F DeSanto | Art Unit 3763 |

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

THE REPLY FILED 26 January 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 3 months from the mailing date of the final rejection.
 b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The reply was filed after the date of filing a Notice of Appeal, but prior to the date of filing an appeal brief. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
 (a) They raise new issues that would require further consideration and/or search (see NOTE below);
 (b) They raise the issue of new matter (see NOTE below);
 (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 (d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. Applicant's reply has overcome the following rejection(s): The 112 Rejection.

6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. For purposes of appeal, the proposed amendment(s): a) will not be entered; or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____

Claim(s) objected to: _____

Claim(s) rejected: 23-76.

Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

The applicant's arguments have been considered but do not place the application in condition for allowance. The applicant is arguing two main points. The first point is that the needle is not the same size as the claimed invention. According to paragraph [0053] Paques discloses the same size of the needle. This is what is claimed, and therefore the prior art reads on this limitation. The applicant also argues, that Paques fails to teach the piercing being advanced into the eye. The examiner disagrees with the applicant's interpretation of the prior art, because the prior art discloses the needle being used to pierce the eye, it must advance into the eye. If the membrane of the eye is pierced, the needle must travel into the eye, and thus fulfill the limitation of the claimed invention. Therefore, the examiner is keeping his rejections.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). _____

13. Other: Information about the outer diameter of a 25 gauge needle.

Continuation of 3. NOTE: The amendments to the claims, change the scope of the claims, and thus require further consideration and possibly a new search.

Matthew

2/21/65

Adrian

NICHOLAS D. LIGGINSKI
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700

The table below shows the gauge sizes in millimeters to get a concrete idea of what the gauges really mean.

| gauge | outer | inner | gauge | outer | inner |
|-------|-------|-------|-------|-------|-------|
| 30 | 0.31 | 0.15 | 17 | 1.50 | 1.04 |
| 27 | 0.41 | 0.20 | 16 | 1.65 | 1.19 |
| 26 | 0.46 | 0.25 | 15 | 1.83 | 1.32 |
| 25 | 0.51 | 0.25 | 14 | 2.11 | 1.60 |
| 23 | 0.64 | 0.33 | 13 | 2.41 | 1.80 |
| 22 | 0.71 | 0.41 | 12 | 2.77 | 2.16 |
| 21 | 0.81 | 0.51 | 11 | 3.05 | 2.39 |
| 20 | 0.91 | 0.58 | 10 | 3.40 | 2.69 |
| 19 | 1.07 | 0.69 | 8 | 4.19 | 3.43 |
| 18 | 1.27 | 0.84 | 7 | 4.57 | 3.81 |

Typical Injector Sizes

IV and SC injectors normally use syringes with gauges of 27, 28, and 29. IM injectors normally use wider needles such 21 or 23.

*by Dr. H © 2001
Last Modified: 9 January 2004*

Right to Life * Exchanges * Gauging Syringes

angry * curious * worried * user * sick * bored
my books * locate * contact * meta site * letters